ClinicaliQ Trial Snapshot
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy — Active Not Recruiting • Phase III • NCT05444257.
- Long-term study showing VX-121 combination therapy is safe and effective for treating cystic fibrosis patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis. Conditions: Cystic Fibrosis Interventions: VX-121/TEZ/D-IVA Lead Sponsor: Vertex Pharmaceuticals Incorporated Planned Enrollment: 822 participants